Trial Profile

PrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Larotrectinib (Primary)
Indications CNS cancer; Gastrointestinal cancer; Head and neck cancer; Lung cancer; Malignant melanoma; Soft tissue sarcoma; Solid tumours
Focus Adverse reactions
Acronyms ON-TRK
Sponsors Bayer

Most Recent Events

29 Oct 2024 Planned number of patients changed from 300 to 150.
07 Jun 2022 Trial design, published in the BMC Cancer
22 Nov 2021 Planned End Date changed from 31 Mar 2028 to 31 Mar 2030.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com